First Huntington’s patient dosed in Phase 2/3 trial testing SKY-0515
The first Huntington’s disease patient has been dosed in a Phase 2/3 clinical trial testing SKY-0515, Skyhawk Therapeutics‘ oral disease-modifying therapy, in adults with the neurodegenerative condition. The study, dubbed FALCON-HD (NCT06873334), is expected to enroll up to…